Irinotecan Hydrochloride Injection USP 20 mg

Irinotecan Hydrochloride Injection USP 20 mg is a cancer treatment medication used in chemotherapy. This intravenous solution is manufactured by Pfizer Canada ULC and is designed for specific therapeutic uses in oncology.

Irinotecan Hydrochloride Injection is primarily used in the treatment of certain types of cancer. It is often administered as part of a chemotherapy regimen to target and inhibit the growth of cancer cells. The medication is typically prescribed by healthcare professionals for specific oncological conditions.

Common effects of Irinotecan Hydrochloride Injection may include nausea, vomiting, and diarrhea. Some patients may also experience fatigue or changes in blood cell counts. These effects can vary widely among individuals and should be discussed with a healthcare provider.

Irinotecan Hydrochloride Injection should be handled with care and administered under the supervision of a healthcare professional. It is important to follow all safety guidelines and storage instructions provided. Patients should be monitored for any adverse reactions during and after treatment.

Irinotecan Hydrochloride Injection may interact with other medications, including those that affect the liver or bone marrow. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of the treatment.